CN107652254A - A kind of method for preparing butyrolactone derivative - Google Patents

A kind of method for preparing butyrolactone derivative Download PDF

Info

Publication number
CN107652254A
CN107652254A CN201711126335.8A CN201711126335A CN107652254A CN 107652254 A CN107652254 A CN 107652254A CN 201711126335 A CN201711126335 A CN 201711126335A CN 107652254 A CN107652254 A CN 107652254A
Authority
CN
China
Prior art keywords
formula
butyrolactone derivative
compound shown
compound
preparing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201711126335.8A
Other languages
Chinese (zh)
Inventor
胡志刚
许良志
何大荣
杜小鹏
钱祝进
何勇
刘庄子
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Anhui Huasheng Medical Technology Co Ltd
Original Assignee
Anhui Huasheng Medical Technology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anhui Huasheng Medical Technology Co Ltd filed Critical Anhui Huasheng Medical Technology Co Ltd
Priority to CN201711126335.8A priority Critical patent/CN107652254A/en
Publication of CN107652254A publication Critical patent/CN107652254A/en
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/26Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D307/30Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/32Oxygen atoms
    • C07D307/33Oxygen atoms in position 2, the oxygen atom being in its keto or unsubstituted enol form
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24Oxygen or sulfur atoms
    • C07D207/262-Pyrrolidones
    • C07D207/2632-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
    • C07D207/272-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

The invention discloses a kind of method for preparing butyrolactone derivative, comprise the following steps:(1) compound shown in formula (II) is split with chiral phenyl ethylamine, obtains the compound shown in formula (III);(2) compound shown in formula (III) is obtained into the compound shown in formula (IV) through borane reduction carboxyl;(3) compound shown in formula (IV) is hydrolyzed into cyano group in the basic conditions, obtains the carboxylic acid derivates shown in formula (V), then the butyrolactone derivative shown in acquisition formula (I) is reacted through dehydration condensation.The advantage of the invention is that:A kind of brand-new butyrolactone derivative synthetic method is provided, the cost of synthesis material is cheap, and only needs 5 steps to react, it is possible to substantially reduces production cost.Synthetic route is as follows:

Description

A kind of method for preparing butyrolactone derivative
Technical field
The present invention relates to organic synthesis technical field, is more particularly to a kind of method for preparing butyrolactone derivative.
Background technology
Butyrolactone derivative shown in lower formula (I) is new antiepileptic medicine Bu Waxitan (Brivaracetam) synthesis Key intermediate.
At present, has the more document reports synthetic method of above-mentioned butyrolactone derivative, for example, patent document Following synthetic method is reported in WO2016/191435, wherein using R- epoxychloropropane as raw material, is contracted with diethyl malonate Close, then with ethyl phosphonium bromide reactive magnesium, last decarboxylation obtains key intermediate butyrolactone derivative, but its cost is costly.
And for example, document Hughes, G. et al., J.Am.Chem.Soc.2003, report is with positive penta in 125,11253-11258 Aldehyde is raw material, through cyclization, reduction, most above-mentioned butyrolactone derivative is obtained through asymmetric reduction afterwards, wherein using valuable chirality Catalyst and part, and it is difficult to keep high chiral purity.And document Rudroff, F. et al., Adv.Synth.Catal.2007, report uses expensive biology enzyme using 1- amylenes as raw material after cyclization in 349,1436-1444 Catalyst, oxidation ring expansion obtain above-mentioned butyrolactone derivative.
Therefore, find that a kind of step is simple, production cost is low, regioselectivity is strong, the butyrolactone derivative of high income Synthetic method is the current technical problem for being badly in need of solving.
The content of the invention
The technical problems to be solved by the invention are the provision of a kind of new method for preparing butyrolactone derivative.
The present invention is that solve above-mentioned technical problem by the following technical programs:
A kind of method for preparing butyrolactone derivative, comprises the following steps:
(1) compound shown in formula (II) is split with chiral phenyl ethylamine, obtains the compound shown in formula (III);
(2) compound shown in formula (III) is obtained into the compound shown in formula (IV) through borane reduction carboxyl;
(3) compound shown in formula (IV) is hydrolyzed into cyano group in the basic conditions, obtains the carboxylic acid shown in formula (V) and derive Thing, then react the butyrolactone derivative shown in acquisition formula (I) through dehydration condensation;
Preferably, the preparation method comprises the following steps:
(1) compound shown in formula (II) is dissolved in toluene, chiral phenyl ethylamine is added at 50~70 DEG C and is stirred, from 15~30 DEG C are so cooled to, crystallization and filtration is separated out and collects crystallization, suspension crystallization, adjust pH to 2, be sufficiently stirred rear liquid separation, wash Wash organic phase, decompression is spin-dried for, the compound shown in acquisition formula (III);
(2) compound shown in formula (III) is dissolved in tetrahydrofuran and is cooled to 0 DEG C, addition tetrahydrofuran borine network Compound, 20~30 DEG C be stirred overnight after be added dropwise aqueous hydrochloric acid solution, stir 0.5~2 hour, washed after dilution, dry and be spin-dried for molten Agent, obtain the compound shown in formula (IV);
(3) compound shown in formula (IV) is suspended in the mixture of second alcohol and water, adds NaOH, backflow 10~30 is small Shi Hou, 0 degree Celsius is cooled to, is spin-dried for after being adjusted to neutrality, obtain the carboxylic acid derivates shown in formula (V);By the carboxylic acid shown in formula (V) Derivative is dissolved in toluene, adds p-methyl benzenesulfonic acid, and backflow overnight, is washed out, is spin-dried for solvent, is evaporated under reduced pressure again, obtains formula (I) butyrolactone derivative shown in.
Preferably, in step (1), the molar equivalent ratio of compound and chiral phenyl ethylamine shown in formula (II) is 1:0.5 ~2.
Preferably, chiral phenyl ethylamine is (S)-phenyl ethylamine.
Preferably, in step (1), the reagent of the suspension crystallization is methyl tertiary butyl ether(MTBE);And/or
The reagent of the regulation pH is sodium bisulphate solution;And/or
The reagent of the washing is saturated aqueous common salt.
Preferably, in step (2), 15~40mL tetrahydrofuran borine networks are added in the compound shown in per 1g formulas (VI) Compound.
Preferably, in step (2), the process of the dilution is to be diluted with methyl tertiary butyl ether(MTBE);And/or
The process of the washing is to use aqueous hydrochloric acid solution, saturated sodium bicarbonate aqueous solution and saturated common salt water washing successively.
Preferably, in step (3), the mass ratio of compound and NaOH shown in formula (VII) is 4~9:1;And/or
The volume ratio of ethanol and water is 2~4 in the mixture of the second alcohol and water:1.
Preferably, in step (3), the process of the washing is to use water, saturated sodium bicarbonate aqueous solution and saturation successively Brine It.
Purposes of the butyrolactone derivative that synthetic method of the present invention obtains in Bu Waxitan is prepared.
The present invention has advantages below compared with prior art:A kind of brand-new butyrolactone derivative synthetic method is provided, closed Cost into raw material is cheap, and only needs 5 steps to react, it is possible to substantially reduces production cost.
Embodiment
Embodiments of the invention are elaborated below, the present embodiment is carried out lower premised on technical solution of the present invention Implement, give detailed embodiment and specific operating process, but protection scope of the present invention is not limited to following implementation Example.
The preparation of compound shown in the formula of embodiment 1 (II)
Synthetic route is as follows:
N-BuLi (2.5mol/L hexane solution, 10mL) is added in reaction bulb, removes n-hexane under reduced pressure, nitrogen is protected - 78 DEG C are cooled under shield, 10mL tetrahydrofurans dissolving n-BuLi is added, adds diethylamine (365mg, 5mmol).Will reaction Liquid is warming up to 0 DEG C and stirred 15 minutes, is cooled to -78 DEG C again, positive valeric acid (1.15g, 11.3mmol) tetrahydrofuran is added dropwise (10mL) solution, 0 DEG C is warming up to after being added dropwise and is reacted 30 minutes.Reaction solution is cooled to -78 DEG C, bromoacetonitrile is added dropwise Tetrahydrofuran (10mL) solution of (1.34g, 11.3mmol), then heat to room temperature reaction 24 hours.Gone out instead with 80mL water quenchings Liquid is answered, then is extracted (50mL × 3) with methyl tertiary butyl ether(MTBE).Aqueous phase adjusts pH=1 with concentrated hydrochloric acid, and (50mL is extracted with ethyl acetate × 3), anhydrous magnesium sulfate is dried, and is concentrated under reduced pressure into dry, obtains the compound 2- cyanogen methylvaleric acid 1.24g shown in formula (II), yield For 78%.High resolution mass spectrum (ESI+):C7H10NO2- theoretical values 140.0717, measured value 140.0713.
The synthesis of butyrolactone derivative shown in the formula of embodiment 2 (I)
Synthetic route is as follows:
(1) compound (28.2g, 1 equivalent) shown in formula (II) is dissolved in 300mL toluene, at 60 DEG C add (S)- Phenyl ethylamine (25.4g, 1.05 equivalents) simultaneously stirs 0.5 hour, naturally cools to 20 DEG C, separates out crystallization and filtration and collects crystallization, will This crystallization is suspended in 500mL methyl tertiary butyl ether(MTBE)s, is added 1N (mol/L) sodium bisulphate solution regulation pH to 2, is sufficiently stirred Liquid separation afterwards, with 250mL saturated common salt water washing organic phases, decompression is spin-dried for, and is obtained the compound shown in formula (III) and (10.7g, is received Rate 38%).
(2) compound (10g, 1 equivalent) shown in formula (III) is dissolved in 200mL tetrahydrofurans and is cooled to 0 DEG C, added Enter 280mL tetrahydrofurans borane complex (1M tetrahydrofurans, 4 equivalents), 20~30 DEG C be stirred overnight after 100mL 1N salt is added dropwise Aqueous acid, stir 1 hour, diluted with 500mL methyl tertiary butyl ether(MTBE)s, successively with 250mL 1N aqueous hydrochloric acid solutions, 250mL saturations Sodium bicarbonate aqueous solution, 250mL saturated common salt water washings, dry and be spin-dried for solvent, obtain the compound shown in formula (IV) (7.7g, yield 85%).High resolution mass spectrum (ESI+):C7H14NO+ theoretical values 128.1070, measured value 128.1063.
(3) compound (20.3g, 1 equivalent) shown in formula (IV) is suspended in the mixture of 30mL ethanol and 10mL water, NaOH (3g) is added, after flowing back 20 hours, 0 degree Celsius is cooled to, is spin-dried for after being adjusted to neutrality with 1N hydrochloric acid, obtain intermediate formula (V) crude product of the carboxylic acid derivates shown in.This crude product is directly suspended in 300mL toluene, addition p-methyl benzenesulfonic acid (41.3g, 1.5 equivalents), backflow is eaten with 100mL water, 100mL saturated sodium bicarbonate aqueous solutions and 100mL saturations successively overnight, by reaction solution Salt water washing, it is spin-dried for solvent and obtains crude compound, then the butyrolactone derivative for being evaporated under reduced pressure to obtain shown in formula (I) (12g, is received Rate 59%).High resolution mass spectrum (ESI+):C7H13O2+ theoretical values 129.0910, measured value 129.0903.
The synthesis of butyrolactone derivative shown in the formula of embodiment 3 (I)
(1) compound (28.2g, 1 equivalent) shown in formula (II) is dissolved in 300mL toluene, at 50 DEG C add (S)- Phenyl ethylamine (0.5 equivalent) simultaneously stirs 0.3 hour, naturally cools to 15 DEG C, separates out crystallization and filtration and collects crystallization, and this crystallization is outstanding Float in 500mL methyl tertiary butyl ether(MTBE)s, add 1N (mol/L) sodium bisulphate solution regulation pH to 2, be sufficiently stirred rear liquid separation, With 250mL saturated common salt water washing organic phases, decompression is spin-dried for, and obtains the compound (5.1g, yield 29%) shown in formula (III).
(2) compound (10g, 1 equivalent) shown in formula (III) is dissolved in 200mL tetrahydrofurans and is cooled to 0 DEG C, added Enter 150mL tetrahydrofurans borane complex (1M tetrahydrofurans, 4 equivalents), 20~30 DEG C be stirred overnight after 100mL 1N salt is added dropwise Aqueous acid, stir 0.5 hour, diluted with 500mL methyl tertiary butyl ether(MTBE)s, satisfied successively with 250mL 1N aqueous hydrochloric acid solutions, 250mL And sodium bicarbonate aqueous solution, 250mL saturated common salt water washings, dry and be spin-dried for solvent, obtain the compound shown in formula (IV) (4.8g, yield 76%).High resolution mass spectrum (ESI+):C7H14NO+ theoretical values 128.1070, measured value 128.1063.
(3) compound (12g) shown in formula (IV) is suspended in the mixture of 20mL ethanol and 10mL water, adds NaOH (3g), after flowing back 10 hours, 0 degree Celsius is cooled to, is spin-dried for after being adjusted to neutrality with 1N hydrochloric acid, is obtained shown in intermediate formula (V) The crude product of carboxylic acid derivates.This crude product is directly suspended in 300mL toluene, adds p-methyl benzenesulfonic acid (41.3g, 1.5 equivalents), Reaction solution overnight, is used 100mL water, 100mL saturated sodium bicarbonate aqueous solutions and 100mL saturated common salt water washings by backflow successively, It is spin-dried for solvent and obtains crude compound, then is evaporated under reduced pressure to obtain the butyrolactone derivative (8g, yield 43%) shown in formula (I).It is high Resolution Mass Spectrometry (ESI+):C7H13O2+ theoretical values 129.0910, measured value 129.0903.
The synthesis of butyrolactone derivative shown in the formula of embodiment 4 (I)
(1) compound (28.2g, 1 equivalent) shown in formula (II) is dissolved in 300mL toluene, at 70 DEG C add (S)- Phenyl ethylamine (2 equivalent) simultaneously stirs 1 hour, naturally cools to 30 DEG C, separates out crystallization and filtration and collects crystallization, this crystallization is suspended in In 500mL methyl tertiary butyl ether(MTBE)s, 1N (mol/L) sodium bisulphate solution regulation pH to 2 is added, rear liquid separation is sufficiently stirred, uses 250mL saturated common salt water washing organic phases, decompression are spin-dried for, and obtain the compound (9.8g, yield 36%) shown in formula (III).
(2) compound (10g, 1 equivalent) shown in formula (III) is dissolved in 200mL tetrahydrofurans and is cooled to 0 DEG C, added Enter 400mL tetrahydrofurans borane complex (1M tetrahydrofurans, 4 equivalents), 20~30 DEG C be stirred overnight after 100mL 1N salt is added dropwise Aqueous acid, stir 2 hours, diluted with 500mL methyl tertiary butyl ether(MTBE)s, successively with 250mL 1N aqueous hydrochloric acid solutions, 250mL saturations Sodium bicarbonate aqueous solution, 250mL saturated common salt water washings, dry and be spin-dried for solvent, obtain the compound shown in formula (IV) (7.1g, yield 82%).High resolution mass spectrum (ESI+):C7H14NO+ theoretical values 128.1070, measured value 128.1063.
(3) compound (27g) shown in formula (IV) is suspended in the mixture of 40mL ethanol and 10mL water, adds NaOH (3g), after flowing back 30 hours, 0 degree Celsius is cooled to, is spin-dried for after being adjusted to neutrality with 1N hydrochloric acid, is obtained shown in intermediate formula (V) The crude product of carboxylic acid derivates.This crude product is directly suspended in 300mL toluene, adds p-methyl benzenesulfonic acid (41.3g, 1.5 equivalents), Reaction solution overnight, is used 100mL water, 100mL saturated sodium bicarbonate aqueous solutions and 100mL saturated common salt water washings by backflow successively, It is spin-dried for solvent and obtains crude compound, then is evaporated under reduced pressure to obtain the butyrolactone derivative (10.5g, yield 52%) shown in formula (I). High resolution mass spectrum (ESI+):C7H13O2+ theoretical values 129.0910, measured value 129.0903.
The butyrolactone derivative that embodiment 2-4 is obtained can be used for preparing Bu Waxitan.
The foregoing is merely illustrative of the preferred embodiments of the present invention, is not intended to limit the invention, all essences in the present invention All any modification, equivalent and improvement made within refreshing and principle etc., should be included in the scope of the protection.

Claims (10)

  1. A kind of 1. method for preparing butyrolactone derivative, it is characterised in that comprise the following steps:
    (1) compound shown in formula (II) is split with chiral phenyl ethylamine, obtains the compound shown in formula (III);
    (2) compound shown in formula (III) is obtained into the compound shown in formula (IV) through borane reduction carboxyl;
    (3) compound shown in formula (IV) is hydrolyzed into cyano group in the basic conditions, obtains the carboxylic acid derivates shown in formula (V), then Through the butyrolactone derivative shown in dehydration condensation reaction acquisition formula (I);
  2. 2. the method according to claim 1 for preparing butyrolactone derivative, it is characterised in that comprise the following steps:
    (1) compound shown in formula (II) is dissolved in toluene, chiral phenyl ethylamine is added at 50~70 DEG C and is stirred, it is naturally cold But to 15~30 DEG C, separate out crystallization and filtration and collect crystallization, suspension crystallization, adjust pH to 2, be sufficiently stirred rear liquid separation, washing has Machine phase, decompression are spin-dried for, and obtain the compound shown in formula (III);
    (2) compound shown in formula (III) is dissolved in tetrahydrofuran and is cooled to 0 DEG C, add tetrahydrofuran borane complex, 20~30 DEG C be stirred overnight after be added dropwise aqueous hydrochloric acid solution, stir 0.5~2 hour, washed after dilution, dry and be spin-dried for solvent, obtained Obtain the compound shown in formula (IV);
    (3) compound shown in formula (IV) is suspended in the mixture of second alcohol and water, adds NaOH, flowed back 10~30 hours Afterwards, 0 degree Celsius is cooled to, is spin-dried for after being adjusted to neutrality, obtains the carboxylic acid derivates shown in formula (V);Carboxylic acid shown in formula (V) is spread out Biology is dissolved in toluene, adds p-methyl benzenesulfonic acid, and backflow overnight, is washed out, is spin-dried for solvent, is evaporated under reduced pressure again, obtains formula (I) Shown butyrolactone derivative.
  3. 3. the method according to claim 1 or 2 for preparing butyrolactone derivative, it is characterised in that in step (1), formula (II) the molar equivalent ratio of compound and chiral phenyl ethylamine shown in is 1:0.5~2.
  4. 4. the method according to claim 3 for preparing butyrolactone derivative, it is characterised in that the chiral phenyl ethylamine is (S)-phenyl ethylamine.
  5. 5. the method according to claim 2 for preparing butyrolactone derivative, it is characterised in that described outstanding in step (1) The reagent of floating crystallization is methyl tertiary butyl ether(MTBE);And/or
    The reagent of the regulation pH is sodium bisulphate solution;And/or
    The reagent of the washing is saturated aqueous common salt.
  6. 6. the method according to claim 2 for preparing butyrolactone derivative, it is characterised in that in step (2), per 1g formulas (VI) 15~40mL tetrahydrofuran borane complexes are added in the compound shown in.
  7. 7. the method according to claim 1 or 2 for preparing butyrolactone derivative, it is characterised in that in step (2), institute The process for stating dilution is to be diluted with methyl tertiary butyl ether(MTBE);And/or
    The process of the washing is to use aqueous hydrochloric acid solution, saturated sodium bicarbonate aqueous solution and saturated common salt water washing successively.
  8. 8. the method according to claim 2 for preparing butyrolactone derivative, it is characterised in that in step (3), formula (VII) mass ratio of compound and NaOH shown in is 4~9:1;And/or
    The volume ratio of ethanol and water is 2~4 in the mixture of the second alcohol and water:1.
  9. 9. the method according to claim 2 for preparing butyrolactone derivative, it is characterised in that described to wash in step (3) The process washed is to use water, saturated sodium bicarbonate aqueous solution and saturated common salt water washing successively.
  10. 10. the butyrolactone derivative that the synthetic method any one of claim 1 to 9 obtains is in Bu Waxitan is prepared Purposes.
CN201711126335.8A 2017-11-14 2017-11-14 A kind of method for preparing butyrolactone derivative Pending CN107652254A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201711126335.8A CN107652254A (en) 2017-11-14 2017-11-14 A kind of method for preparing butyrolactone derivative

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201711126335.8A CN107652254A (en) 2017-11-14 2017-11-14 A kind of method for preparing butyrolactone derivative

Publications (1)

Publication Number Publication Date
CN107652254A true CN107652254A (en) 2018-02-02

Family

ID=61121625

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201711126335.8A Pending CN107652254A (en) 2017-11-14 2017-11-14 A kind of method for preparing butyrolactone derivative

Country Status (1)

Country Link
CN (1) CN107652254A (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109400556A (en) * 2018-12-29 2019-03-01 上海应用技术大学 A kind of synthetic method of D- (-)-pantoic acid lactone
CN111349007A (en) * 2018-12-24 2020-06-30 浙江京新药业股份有限公司 Preparation method of (R) -4-propyl-dihydrofuran-2-ketone and preparation intermediate thereof
CN111675643A (en) * 2020-06-15 2020-09-18 浙江天宇药业股份有限公司 Preparation method of brivaracetam
KR20210018454A (en) * 2018-06-22 2021-02-17 푸지안 하이시 파마슈티칼스 컴퍼니 리미티드 Compounds for the synthesis of brivaracetam intermediates and bulk pharmaceuticals and their uses
WO2021253162A1 (en) * 2020-06-15 2021-12-23 浙江天宇药业股份有限公司 Preparation method for brivaracetam
CN115197178A (en) * 2022-08-24 2022-10-18 四川诺非特生物药业科技有限公司 Synthesis method of brivaracetam key intermediate

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009155280A (en) * 2007-12-27 2009-07-16 Mitsubishi Rayon Co Ltd METHOD FOR PRODUCING gamma-BUTYROLACTONE COMPOUND
EP1940811B1 (en) * 2005-10-21 2014-02-26 Bayer Intellectual Property GmbH Heterocyclic compounds with carboxyl isostere groups and their use for the treatment of cardiovascular diseases
CN105837535A (en) * 2016-04-06 2016-08-10 成都拿盛科技有限公司 Synthesis method of substituted chiral gamma-butanolide

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1940811B1 (en) * 2005-10-21 2014-02-26 Bayer Intellectual Property GmbH Heterocyclic compounds with carboxyl isostere groups and their use for the treatment of cardiovascular diseases
JP2009155280A (en) * 2007-12-27 2009-07-16 Mitsubishi Rayon Co Ltd METHOD FOR PRODUCING gamma-BUTYROLACTONE COMPOUND
CN105837535A (en) * 2016-04-06 2016-08-10 成都拿盛科技有限公司 Synthesis method of substituted chiral gamma-butanolide

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ARNAUD SCHÜLE ET AL.: "A Biocatalytic Route to the Novel Antiepileptic Drug Brivaracetam", 《ORGANIC PROCESS RESEARCH & DEVELOPMENT》 *

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7117796B2 (en) 2018-06-22 2022-08-15 福建▲海▼西新▲薬▼▲創▼制有限公司 its use in the synthesis of compounds and intermediates and drug substances of Brivaracetam
KR102544330B1 (en) 2018-06-22 2023-06-20 푸지안 하이시 파마슈티칼스 컴퍼니 리미티드 Compounds for the synthesis of Brivaracetam intermediates and bulk pharmaceuticals and their uses
KR20210018454A (en) * 2018-06-22 2021-02-17 푸지안 하이시 파마슈티칼스 컴퍼니 리미티드 Compounds for the synthesis of brivaracetam intermediates and bulk pharmaceuticals and their uses
JP2021528440A (en) * 2018-06-22 2021-10-21 福建▲海▼西新▲薬▼▲創▼制有限公司 Its use in the synthesis of compounds and intermediates and APIs of Brivaracetam
US11247977B2 (en) 2018-06-22 2022-02-15 Fujian Haixi Pharmaceuticals Co., Ltd. Compound and use thereof in synthesis of brivaracetam intermediate and crude drug
CN111349007A (en) * 2018-12-24 2020-06-30 浙江京新药业股份有限公司 Preparation method of (R) -4-propyl-dihydrofuran-2-ketone and preparation intermediate thereof
CN111349007B (en) * 2018-12-24 2023-03-31 浙江京新药业股份有限公司 Preparation method of (R) -4-propyl-dihydrofuran-2-ketone and preparation intermediate thereof
CN109400556A (en) * 2018-12-29 2019-03-01 上海应用技术大学 A kind of synthetic method of D- (-)-pantoic acid lactone
WO2021253162A1 (en) * 2020-06-15 2021-12-23 浙江天宇药业股份有限公司 Preparation method for brivaracetam
CN111675643B (en) * 2020-06-15 2021-10-26 浙江天宇药业股份有限公司 Preparation method of brivaracetam
CN111675643A (en) * 2020-06-15 2020-09-18 浙江天宇药业股份有限公司 Preparation method of brivaracetam
CN115197178A (en) * 2022-08-24 2022-10-18 四川诺非特生物药业科技有限公司 Synthesis method of brivaracetam key intermediate
CN115197178B (en) * 2022-08-24 2024-04-26 四川诺非特生物药业科技有限公司 Synthesis method of brivaracetam key intermediate

Similar Documents

Publication Publication Date Title
CN107652254A (en) A kind of method for preparing butyrolactone derivative
CN106432030B (en) A kind of preparation method of Bu Waxitan
CN106365986B (en) Compound and preparation method thereof and the purposes in synthesis Bu Waxitan
CN101747273B (en) Preparing method of blonanserin intermediate
CN105367526B (en) A kind of preparation method of high-purity n butylphthalide
CN104177331B (en) The preparation method of bilastine
CN102358747A (en) Rosuvastatin calcium intermediate and method for preparing rosuvastatin calcium intermediate and rosuvastatin calcium
WO2008015977A1 (en) PROCESS FOR PRODUCTION OF (±)-3a,6,6,9a– TETRAMETHYLDECAHYDRONAPHTHO[2,1-b]FURAN-2(1H)-ONE
CN107698543A (en) A kind of preparation method of butyrolactone derivative
CN102942444B (en) Synthesis method of 2,2'-dibromo-9,9'-spirobifluorene
CN113336764B (en) Bipyridine ligand with axial chirality and synthetic method thereof
CN104529908B (en) A kind of preparation method of rosuvastain calcium
CN111454315B (en) Synthesis method of androstane-16-alkene-3 beta-alcohol
CN107663185A (en) A kind of synthetic method of butyrolactone derivative
CN111072450B (en) Synthesis method of allyl alcohol derivative
CN107827845A (en) A kind of method of new synthesis butyrolactone derivative
CN107827844A (en) A kind of method for synthesizing butyrolactone derivative
CN114213424A (en) Synthetic method of furan [3, 2-b ] pyridine derivative
CN103626791B (en) A kind of method of synthesizing 3-amino-4-fluorobenzoic boric acid
CN108084077B (en) Synthetic method of zafirlukast intermediate
CN107759540A (en) A kind of preparation method of butyrolactone derivative
CN109503639A (en) The synthetic method of trans- three potassium fluoborate of -2- substituted cycloalkyl
CN102531865B (en) Preparation method of 1-(2,6,6-trimethylcyclohex-3-enyl) butyl-2-en-1-one
CN101987842A (en) Method for preparing 2-methyl thiophene derivatives
CN107759539A (en) A kind of new method for preparing butyrolactone derivative

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20180202

RJ01 Rejection of invention patent application after publication